首页> 美国卫生研究院文献>Indian Journal of Microbiology >Construction Selection and Immunogenicity of Recombinant Fowlpox Candidate Vaccine Co-expressing HIV-1 gag and gp145
【2h】

Construction Selection and Immunogenicity of Recombinant Fowlpox Candidate Vaccine Co-expressing HIV-1 gag and gp145

机译:共表达HIV-1 gag和gp145的重组禽痘候选疫苗的构建选择和免疫原性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An HIV candidate vaccine for the Chinese population was designed by constructing a recombinant fowlpox virus expressing HIV-1 gag and HIV gp145 proteins via homologous recombination and plaque screening using enhanced green fluorescent protein (EGFP) as the reporter gene. EGFP in the recombinant was then knocked out with the Cre/Loxp system yielding rFPVHg-Hp, which was identified at the genomic, transcriptional and translational levels. The immunogenicity of rFPVHg-Hp was analyzed by measuring levels of HIV-specific antibodies and IFN-γ-secreting splenocytes by enzyme-linked immunosorbent assay and IFN enzyme-linked immune spot test in the BALB/c mouse model. Results showed that rFPV could not stimulate HIV-1 specific antibodies or IFN-γ-secreting cells by a single immunization. Meanwhile, in the prime-boost strategy, HIV-p24 antibodies (P < 0.01) and IFN-γ-secreting cells (P < 0.05) were induced strongly by the candidate vaccine after the boost immunization. Thus, both humoral and cellular immunity could be elicited by the candidate vaccine in a prime-boost immunization strategy. This study provides a foundation for future preclinical studies on the HIV rFPVHg-Hp candidate vaccine.
机译:通过使用重组绿色荧光蛋白(EGFP)作为报告基因,通过同源重组和噬菌斑筛选,构建表达HIV-1 gag和HIV gp145蛋白的重组鸡痘病毒,设计了针对中国人群的HIV候选疫苗。然后用Cre / Loxp系统敲除重组体中的EGFP,产生rFPVHg-Hp,可在基因组,转录和翻译水平上鉴定出rFPVHg-Hp。通过在BALB / c小鼠模型中通过酶联免疫吸附试验和IFN酶联免疫斑点试验测量HIV特异性抗体和分泌IFN-γ的脾细胞的水平来分析rFPVHg-Hp的免疫原性。结果表明,rFPV不能通过单次免疫刺激HIV-1特异性抗体或分泌IFN-γ的细胞。同时,在初免-加强策略中,加强免疫后的候选疫苗强烈诱导了HIV-p24抗体(P <0.01)和IFN-γ分泌细胞(P <0.05)。因此,候选疫苗可以在初免-加强免疫策略中引发体液免疫和细胞免疫。该研究为HIV rFPVHg-Hp候选疫苗的未来临床前研究提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号